Abstract
The selection of first-line treatment for Type 2 Diabetes (T2D)—typically between metformin and alternatives like DPP-4 inhibitors or sulfonylureas—is influenced by clinical factors such as kidney function (eGFR) and provider-specific preferences. This study analyzes treatment variation across a cohort of 10,643 patients using a novel statistical framework. By comparing models with and without provider-specific random effects using a Generalized Likelihood Ratio Test (GLRT), we found significant variation in treatment decisions attributable to providers (p < 0.0001), particularly at lower eGFR levels where clinical guidelines are less definitive. These findings suggest that provider preference plays a substantial role in T2D management, highlighting the need for further research into the appropriateness of this variation.
Introduction
Metformin is widely regarded as the gold-standard first-line therapy for Type 2 Diabetes (T2D) due to its efficacy, low cost, and favorable safety profile. However, its use is historically restricted in patients with significant renal impairment, as measured by the estimated glomerular filtration rate (eGFR), due to concerns regarding lactic acidosis. While the American Diabetes Association (ADA) and FDA updated guidelines in 2016 to allow metformin use in patients with moderate renal impairment (eGFR 30–60 mL/min/1.73 m²), clinical adoption of these updates can be inconsistent.
This study investigates the drivers behind first-line treatment selection, specifically examining the extent to which treatment variation is dictated by patient clinical characteristics versus individual provider preferences.
Methods
The researchers utilized health insurance claims data from a large provider in the Northeast United States, spanning the years 2012 to 2021.
Cohort Selection
The initial cohort consisted of 10,643 patients who were observed prior to their first-line treatment, had available eGFR results, and no history of Type 1 or gestational diabetes. For the provider-specific analysis, the cohort was restricted to 2,271 patients treated by 173 providers who had managed at least 10 patients each.
Statistical Framework
To isolate the impact of provider preference, the study employed a novel statistical approach comparing two families of generalized linear models:
- Model 0 (Patient-only): Predicted the probability of receiving metformin based on patient features, including age, sex, eGFR, history of heart failure, and the date of treatment.
- Model 1 (Patient + Provider): Incorporated the same patient features but added provider-specific random effects (random intercepts and random slopes for eGFR). This allowed the model to account for different baseline tendencies and sensitivities to kidney function among doctors.
The researchers then performed a Generalized Likelihood Ratio Test (GLRT) to determine if the inclusion of provider-specific data significantly improved the model's ability to explain the observed treatment decisions.
Results
The analysis confirmed that while eGFR is a primary driver of treatment choice, provider preference is a statistically significant independent factor.
The Impact of Kidney Function
As expected, metformin prescription rates were strongly correlated with eGFR. Among patients with an eGFR ≥ 90, 88.8% received metformin. This dropped to 14.1% for patients with an eGFR < 30, where the drug is strictly contraindicated.
Provider-Level Variation
The GLRT yielded a G-statistic of 387.3 (p < 0.0001), indicating that provider identity significantly influences the choice of first-line therapy even after controlling for all available patient-level clinical data. Interestingly, the study did not identify specific "outlier" providers; rather, the variation was distributed across the entire population of physicians.
The "Gray Zone"
The most pronounced variation between providers occurred in the "gray zone" of renal function—specifically eGFR levels between 30 and 60. In this range, the probability of a patient receiving metformin varied significantly depending on their doctor. For a hypothetical patient with an eGFR of 50, some providers had a nearly 100% probability of prescribing metformin, while others dropped to near 0%, preferring DPP-4 inhibitors or sulfonylureas instead.
Discussion
The findings suggest a "spectrum of practice" across the medical community. In clinical scenarios where guidelines are less rigid or have recently changed, individual "practice styles" become a dominant factor in decision-making. This suggests that the "who" of medical care is often as influential as the patient's clinical data.
Limitations
The study's reliance on claims data means certain nuances, such as patient-reported gastrointestinal intolerance to metformin or specific cost-sharing concerns, were not captured. Additionally, the data reflects a specific geographic region and may not be generalizable to all healthcare systems.
Conclusion
This research demonstrates that provider preference is a major determinant in Type 2 Diabetes treatment, particularly when clinical guidelines allow for interpretation. The novel statistical approach used here provides a robust framework for evaluating provider variation in other areas of medicine. Future research should focus on whether this variation impacts long-term patient outcomes, which could help refine clinical guidelines and reduce unnecessary treatment disparities.
Summary updated